Business Context and Reporting Period
This Form 8-K, dated July 6, 2022, reports on Social Capital Suvretta Holdings Corp. III ("SCS"), a Cayman Islands-based special purpose acquisition company (SPAC) trading under the symbol DNAC. The filing details the outcome of an Extraordinary General Meeting held on July 6, 2022, regarding a proposed business combination with ProKidney LP, an Irish limited partnership focused on cell therapy.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period. As a SPAC in the pre-combination phase, the document focuses on capital structure and voting outcomes rather than operational financial performance.
- Outstanding Shares (as of June 2, 2022): 25,640,000 Class A ordinary shares and 6,250,000 Class B ordinary shares.
- Par Value: $0.0001 per share.
- Voting Participation: 25,017,018 ordinary shares (approximately 78.45% of outstanding shares) were present in person or by proxy.
Material Changes and Voting Results
The primary event reported is the adjournment of the shareholder meeting to allow additional time to satisfy conditions for the business combination, specifically regarding Nasdaq Capital Market listing approval. Shareholders voted on the Adjournment Proposal with the following results:
| Vote Category | Number of Shares |
|---|---|
| For | 23,293,376 |
| Against | 1,716,287 |
| Abstain | 7,355 |
The proposal was approved by the shareholders.
Guidance, Outlook, and Risks
Outlook and Next Steps: SCS announced it will reconvene the Extraordinary General Meeting on July 11, 2022, at 8:30 a.m. Eastern Time. The meeting will be held physically in New York and virtually via webcast to continue the process of approving the Business Combination Agreement.
Risks and Contingencies: The filing outlines significant risks associated with the proposed transaction, including:
- Failure to complete the transaction in a timely manner or by the business combination deadline.
- Inability to satisfy conditions to closing, such as shareholder approval and minimum cash requirements.
- Failure to obtain Nasdaq listing approval for the combined company.
- Disruption to ProKidney's operations and employee retention.
- Volatility in SCS securities prices due to regulatory changes and industry competition.
- Uncertainties inherent in cell therapy research and development timelines.
Investor Verification Checklist
- Verify the outcome of the reconvened Extraordinary General Meeting scheduled for July 11, 2022.
- Confirm whether the combined company has received listing approval from The Nasdaq Capital Market.
- Review the definitive proxy statement (Schedule 14A) for detailed risk factors and transaction terms.
- Monitor the status of the private placement and minimum cash condition required for closing.
- Check for any updates regarding the business combination deadline and potential extensions.